Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT01126086
- Locations
- 🇺🇸
Investigational Site Number 840001, Orlando, Florida, United States
🇺🇸Investigational Site Number 840002, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 840003, Miami Gardens, Florida, United States
Comparative Safety and Efficacy Evaluation Between Dermacyd Silver and Glycerine Vegetal Soap Granado Traditional
- Conditions
- Hygiene
- Interventions
- Drug: Dermacid Silver (Lactic acid)
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2010-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT01126606
- Locations
- 🇧🇷
Sanofi-Aventis Administrative Office, Sao Paulo, Brazil
Pharmacodynamic and Pharmacokinetic Study of 2 Different Dose Regimen of Clopidogrel in CYP2C19 Genotyped Healthy Subjects
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2011-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT01123824
- Locations
- 🇩🇪
Sanofi-Aventis Administrative Office, Berlin, Germany
Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: NPH insulin (insulin isophane)Drug: Regular insulin
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 72
- Registration Number
- NCT01122979
- Locations
- 🇧🇷
Investigational Site Number 076-013, São Paulo, Brazil
🇧🇷Investigational Site Number 076-007, Curitiba, Brazil
🇧🇷Investigational Site Number 076-005, São Paulo, Brazil
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
- Conditions
- Pancreatic Neoplasms
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 108
- Registration Number
- NCT01121848
- Locations
- 🇨🇦
Investigational Site Number 124011, Greenfield Park, Canada
🇨🇦Investigational Site Number 124010, Hamilton, Canada
🇨🇦Investigational Site Number 124008, Sudbury, Canada
Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 934
- Registration Number
- NCT01121835
- Locations
- 🇨🇴
Investigational Site Number 170003, Bucaramanga, Colombia
🇨🇴Investigational Site Number 170004, Pereira, Colombia
🇨🇳Investigational Site Number 156012, Haikou, China
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT01120314
- Locations
- 🇺🇸
Investigational Site Number 840003, Miami Gardens, Florida, United States
🇺🇸Investigational Site Number 840004, St. Paul, Minnesota, United States
🇺🇸Investigational Site Number 840005, Orlando, Florida, United States
Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2017-06-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 223
- Registration Number
- NCT01118728
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 978
- Registration Number
- NCT01117350
- Locations
- 🇺🇸
Investigational Site Number 840026, Longmont, Colorado, United States
🇺🇸Investigational Site Number 840007, Dallas, Texas, United States
🇺🇸Investigational Site Number 840020, Uniontown, Pennsylvania, United States
Safety, Tolerability and Pharmacokinetics of SAR113945 Following Intra-articular Administration in Patients With Knee Osteoarthritis
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2011-03-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT01113333
- Locations
- 🇩🇪
Sanofi-Aventis Investigational Site Number 276001, Berlin, Germany